Russia releases first batch of its COVID-19 vaccine 'Sputnik V' for public use

Russian authorities have released first batch of its COVID-19 vaccine 'Sputnik V' for use of general public hoping that majority of Russians would be vaccinated against dely virus within months. vaccine which was jointly developed by government and Gamaleya institute was publically revealed on August 12. Despite being in third phase of trial, production of vaccine was started soon reafter.

A statement released by Russian Health ministry stated that regional deliveries of vaccine has been planned in nearest future. vaccine has developed by Russia's Gamaleya National Research Center of Epidemiology and Microbiology and Russian Direct Investment Fund (RDIF). Meanwhile, speaking to international media reporters, Moscow Mayor Sergey Sobyanin expressed hope that majority of capital's residents would be vaccinated in coming months.

" first batch of 'Gam-COVID-Vac' (Sputnik V) vaccine for prevention of new coronavirus infection, developed by Gamaleya National Research Center of Epidemiology and Microbiology of Ministry of Health of Russia, has passed necessary quality tests in laboratories of Roszdravnzor (medical device regulator) and has been released into civil circulation," ministry said in a statement.

Re: COVID-19: Clinical Trials Of Sputnik-V To Commence In India, Or Countries This Month

Re: Moscow's COVID-19 Death Toll Soars To 4,891 As Russia Tests 'Sputnik V' Vaccine

Clinical trials in India

This comes as CEO of Russian Direct Investment Fund (RDIF) Kirill Dmitriev, on Spetember 7, confirmed that clinical trials of Sputnik V - Russia's COVID vaccine - will be held in September across India and or countries. Apart from India, clinical trials will also be held in Saudi Arabia, UAE, Philippines, and Brazil. Earlier, RDIF h also affirmed that it is in close dialogue with Indian government to manufacture vaccine at a large level. 

" post-registration studies involving more than 40,000 people started in Russia on August 26, before AstraZeneca has started its Phase 3 trial in US with 30,000 participants. Clinical trials in Saudi Arabia, UAE, Philippines, India, and Brazil will begin this month. preliminary results of Phase 3 trial will be published in October-November 2020," ANI quoted RDIF CEO. 

Re: Subramanian Swamy Questions EAM Jaishankar's Scheduled Meeting With Chinese FM In Moscow

Re: Moscow's COVID-19 Death Toll Soars To 4,891 As Russia Tests 'Sputnik V' Vaccine